Browsing by Author "Sarialioglu, Faik"

Now showing 1 - 16 of 16

17 Years Of Pediatric Liver Transplantation Experience For Cirrhosis And Hepatocellular Carcinoma
(2022) Ozcay, Figen; Sezer, Oya Balci; Sarialioglu, Faik; Boyvat, Fatih; Coskun, Mehmet; Reyhan, Nihan Haberal; Haberal, Mehmet; https://orcid.org/0000-0002-3462-7632; AAJ-8097-2021
beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration
(2014) Iseri, Ozlem Darcansoy; Sahin, Feride Iffet; Terzi, Yunus Kasim; Yurtcu, Erkan; Erdem, S. Remzi; Sarialioglu, Faik; 25026350
Context: Propranolol, atenolol, and ICI118,551 are non-selective beta-adrenergic receptor (AR), beta(1)-AR, and beta(2)-AR antagonists, respectively. Objective: We investigated the efficacy of propranolol, atenolol, and ICI118,551 on proliferation, migration, and invasion of non-stimulated breast (MCF7), colon (HT-29), and hepatocellular (HepG2) cancer cells. Materials and methods: beta-AR expression profiling of cells was performed by real time PCR. Cell proliferation was determined by MTT. Boyden chamber and scratch assays were performed to evaluate invasion and migration. Results and discussion: All cell lines expressed beta-ARs. ICI118,551 was the most cytotoxic, whereas atenolol was the least effective beta-AR antagonist for 24, 48, and 72 h. Cell invasion was inhibited by ICI118,551 (45, 46, and 50% for MCF7, HT29, and HepG2, respectively) and propranolol (72, 65, and 90% for MCF7, HT29, and HepG2, respectively). Propranolol, atenolol, and ICI118,551 reduced migration of MCF7, HT-29, and HepG2 cells to varying extents depending on the application concentration and duration. Propranolol and atenolol reduced migration of MCF7 and HT-29 in a concentration-dependent manner, whereas migration of these cells decreased after 48 and 72 h of ICI118,551 applications. Conclusion: Beta(2)-AR antagonist seemed to be the most cytotoxic beta-blocker on non-stimulated cancer cells. Propranolol and ICI118,551 were more effective than atenolol in inhibiting invasion and migration of non-stimulated MCF7 and HT-29 cells; ICI118,551 being the most potent. Concordantly, beta(2)-selective blockage seemed to be more effective for non-stimulated cells. Effect of the selective beta-AR antagonists showed variation depending on the concentration, incubation time, and histological origin of cells.
Can Hepatitis A Vaccine Provide Protection Against COVID-19?
(2020) Sarialioglu, Faik; Apak, Fatma Burcu Belen; Haberal, Mehmet; 0000-0002-9278-6703; 0000-0002-3462-7632; 0000-0002-8257-810X; 32279655; AAJ-8171-2021; AAJ-8097-2021; AAL-7766-2021
Cardiac Evaluation in Children with Hemangiomas
(2016) Erdogan, Ilkay; Sarialioglu, Faik; 0000-0001-6887-3033; 0000-0002-8257-810X; 27665331; ABB-2220-2021; AAL-7766-2021
Objective: Hemangiomas are tumors most commonly encountered in pediatric patients, and are frequently treated with propranolol. However, there are currently no standard methods for evaluating cardiac function in patients prior to propranolol treatment. The present study was designed to aid in the evaluation of pretreatment cardiac and effects of propranolol on vital signs in pediatric hemangioma patients. Methods: A pediatric oncology specialist and a pediatric cardiology specialist examined all patients prior to initiation of propranolol treatment. All patients were examined by the same 2 physicians. Cardiac evaluation included complete echocardiogram and electrocardiography. From September 2009 to January 2014, 146 patients aged 4 days to 10 years were screened. Results: No patient had cardiac contraindication to propranolol. The effect of hemangioma on left ventricle size was examined, but left ventricle dilatation was found in only 3 patients. However, 68 patients had abnormal echocardiogram: 17 had patent foramen ovale, 4 had ventricular septal defect, 9 had atrial septal defect (associated with right heart enlargement), 8 had patent ductus arteriosus, 6 had physiologic pulmonary stenosis, and 1 had an aortic coarctation. No contraindications to propranolol or side effects were observed. However, cardiac anatomic defects were more common in this patient group than in the general population. Conclusion: Hemangiomas in infants or children, even in small or premature infants, can be treated with propranolol without significant cardiac side effects. In addition, large dermal hemangiomas were not found to affect ventricular size in pediatric patients.
A Different Cause for Respiratory Disorder in Children: Cases with Pulmonary Langerhans Cell Histiocytosis
(2017) Asilsoy, Suna; Yazici, Nalan; Demir, Senay; Erbay, Ayse; Kocer, Emrah; Sarialioglu, Faik; https://orcid.org/0000-0003-4465-8229; https://orcid.org/0000-0002-4209-9075; https://orcid.org/0000-0002-8257-810X; 26083968; AAM-5138-2021; AAK-9310-2021; AAL-7766-2021
Background and AimsIn children, complaints of a respiratory disorder are very frequent. Etiology of respiratory illness is a broad spectrum that varies from a simple viral infection to a malignant disorder. Pulmonary Langerhans cell histiocytosis (PLCH) is one of these entities and it is truly rare in children. The aim of this study is to evaluate our patients with PLCH. MethodsPatients who had been diagnosed with PLCH were retrospectively evaluated. Features of medical history, onset of the complaints, date of the diagnosis, chest X-Ray and computed tomography (CT) findings, histopathology and other laboratory investigations were considered. ResultsThere were four cases with PLCH. All of them were male, ages were between 5 months and 16 years. In three cases, major complaints were chronic respiratory problems whereas in one of them there was acute respiratory distress beginning with cough and leading to pneumothorax. In all of the cases, multisystemic involvement was prominent. The diagnosis was proven by histopathology in all of the cases. In two children with smaller age, skin involvement was detected. Time from complaint to diagnosis was minimum 3 months and maximum 3 years. ConclusionPLCH is a rare disorder in children. Pulmonary involvement is generally a component of systemic involvement but in many cases it might have been detected with early respiratory complaints. So, children with chronic respiratory problems should be carefully evaluated and should be followed up for rare entities like PLCH.
Experience of Post-Transplant Lymphoproliferative Disorder (PTLD) After Pediatric Liver Transplant: Incidence, Outcomes and Association with Food Allergy
(2018) Baris, Zeren; Ozcay, Figen; Ozbek, Ozlem; Haberal, Nihan; Sarialioglu, Faik; Haberal, Mehmet; 0000-0002-5214-516X; 0000-0001-9852-9911; 0000-0002-8257-810X; 0000-0002-3462-7632; AAB-4153-2020; ABG-5684-2020; AAK-4587-2021; AAL-7766-2021; AAJ-8097-2021
Hepatitis A susceptibility parallels high COVID-19 mortality
(2021) Sarialioglu, Faik; Belen, Fatma Burcu; Hayran, Kadir Mutlu; 0000-0002-8257-810X; 0000-0002-9278-6703; 32718125; AAL-7766-2021
Background/aim: COVID-19 has become the biggest health problem of this century. It has been hypothesized that immunity against hepatitis A virus (HAV) may provide protection from COVID19. Materials and methods: As of 10 June 2020, the infection had spread to 213 countries, with 7.3 million people infected and 413,733 dead. This data was combined with the World Health Organization susceptibility classification on the worldwide prevalence of HAV, and the relationship between HAV susceptibility and COVID-19 mortality were analyzed. Results: When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19 mortality rates by HAV susceptibility (P <0.001). Using a cut-off of 200/million population, the mortality risk associated with living in a more susceptible country (medium/high) was 27.8 times higher (95% CI for OR: 3.6-213.2) Conclusion: The results of this study showed that, despite confounding factors in different countries, hepatitis A susceptibility of the population may have been correlated with COVID-19 mortality. This observation needs to be confirmed by further studies.
Medulloblastoma: Clinicopathological Correlates of SHH, WNT, and Non-WNT/SHH Molecular Subgroups Analysis and Prognostic Significance: Mono-Institutional Series
(2022) Hasbay, Bermal; Kayaselcuk, Fazilet; Suner, Halil Ibrahim; Sarialioglu, Faik; https://orcid.org/0000-0002-5957-8611; 000832603900001; AAJ-5381-2021
AIM: To reevaluate the medulloblastoma cases according to histomorphological and molecular features, and to investigate the relationship between the prognostic factors of the new WHO classification by applying Beta-catenin, YAP1, GAP1, p53, and INI1 antibodies immunohistochemically. MATERIAL and METHODS: This study includes 41 patients who have been diagnosed with medulloblastoma between 2007-2019 in pathology department. Immunohistochemically, p53, beta-catenin, YAP1, GAP1, and INI1 immune markers were applied, and the relationship between the results and the prognostic parameters was evaluated statistically. RESULTS: When 41 patients were classified into WHO medulloblastoma histological subtype groups according to histomorphological features, 22 (53.7%) patients were classified as classical type, 11 (26.8%) patients as desmoplastic nodular type, and 8 (19.5%) patients as large cell/anaplastic type medulloblastoma. According to their molecular characteristics, 14 (34.1%) patients were in the Non-WNT/SHH group, 5 (12.2%) patients were SHH mutant, 17 (41.5%) patients were SHH wild, and 5 (12.2%) patients were in the WNT active group. There was no statistically significant correlation between age, gender, tumor size, recurrence, Ki67 proliferation index with molecular types and histopathological types. CONCLUSION: In our study, metastasis at the time of diagnosis, histological large cell anaplastic type, immunohistochemical p53 positivity, molecular SHH mutant type were the statistically significant indicators of worse prognosis and shorter survival time.
Neuroblastoma Accompanied by Hyperaldosteronism
(2014) Gulleroglu, Kaan; Bayrakci, Umut; Kinik, Sibel Tulgar; Uslu, Nihal; Atilgan, Alev O. K.; Sarialioglu, Faik; Baskin, Esra; https://orcid.org/0000-0003-1434-3824; https://orcid.org/0000-0002-6733-8669; https://orcid.org/0000-0001-8595-8880; https://orcid.org/0000-0002-8257-810X; https://orcid.org/0000-0003-4361-8508; 25340174; AAJ-8833-2021; ABC-5258-2020; AAK-3333-2021; AAL-7766-2021; B-5785-2018
Background: Tumors known derived from kidneys which take place in secondary hyperaldosteronism etiology are juxtaglomerular cell tumor and Wilms' tumor. Neuroblastoma presenting with hyperaldosteronism is rare. Case: A 15-month-old girl who had been having diarrhea and fever for 2 weeks presented with a 3 day history of bilious vomiting, metabolic acidosis and severe hypokalemia. She was referred to our hospital with the pre-diagnosis of unknown manifest hypertension etiology, diarrhea, and paralytic ileus after having therapy-resistant hypokalemia and severe resistant acidosis. On her examination after being admitted to our clinic, she was weak, unwell and lethargic with a blood pressure of 140/93 mmHg. Due to the hypertension and severe hypokalemia, the patient was considered to be hyperaldosteronism. Serum aldosterone level, plasma renin activity and cortisol level were elevated. Radiologic findings were compatible with neuroblastoma. The patient underwent an abdominal surgery and the mass excision. The histopathological examination was proved neuroblastoma. Conclusion: Hyperaldosteronism can be presented by unexpected atypical forms as in our patient.
Persistent Hyperinsulinemic Hypoglycemia with Pancreatic Teratoma in Infancy: A Case Report
(2020) Cemeroglu, Ayse Pinar; Sarialioglu, Faik; Belen-Apak, Fatma Burcu; Terzi, Yunus Kasim; 0000-0002-8257-810X; 32782239; AAL-7766-2021
Objective: Unusual clinical course Background: Pediatric intraabdominal pancreatic teratomas have been rarely reported. This is the first case of severe hyper-insulinemic hypoglycemia in a 6-month-old infant secondary to an intraabdominal teratoma. The hypoglycemia resolved after surgical removal. Case Rreport: A 6-month-old infant was seen in a pediatric emergency department with complaints of lethargy and abnormal eye movements. She was diagnosed with hyperinsulinemic hypoglycemia and started on diazoxide. A CT and MRI of the abdomen revealed a 165x77x72 mm cyst with a 51x45x30 mm solid structure connecting to the wall of the cyst by a stalk, raising suspicion of a fetus in fetu. The mass had no connection to her pancreas. Following total excision of the intraabdominal mass, her hypoglycemia resolved. Histopathological examination showed immature fetal pancreatic tissue consistent with a mature teratoma. Whole exon sequencing of the infant's peripheral blood showed a negative mutation of ABCC8 and presence of heterozygous variations of HNF1b and IRS1 genes. Conclusions: This is the first case report of an infant with severe hyperinsulinemic hypoglycemia secondary to a pancreatic teratoma. The heterozygous variations of HNF1b and IRS1 genes likely played a role in the embryogenesis, causing a pancreatic teratoma and hyperinsulinemic hypoglycemia.
Primary B-Cell Lymphoma of Liver And Spleen: Report of Two Cases
(2015) Demir, Senay; Gezer, Hasan Ozkan; Yazici, Nalan; Ozdemir, Handan; Torun, Nese; Sarialioglu, Faik; 0000-0002-7528-3557; 0000-0002-8257-810X; 0000-0002-4209-9075; 0000-0002-5597-676X; X-8540-2019; AAL-7766-2021; AAK-9310-2021; AAE-2718-2021; AAM-5138-2021; J-3197-2013
Serum Neuron-specific Enolase Levels in Preterm and Term Newborns and in Infants 1-3 Months of Age
(2015) Abbasoglu, Aslihan; Sarialioglu, Faik; Yazici, Nalan; Bayraktar, Nilufer; Haberal, Aysegul; Erbay, Ayse; 25315754
Background: Elevated serum levels of neuron-specific enolase (NSE) was initially assumed to be specific to neuronal tumors (particularly neuroblastoma), but is now known to accompany nontumoral conditions and tumors other than neuroblastomas. There is a need to establish normal ranges for NSE, especially in early infancy. The aims of this study were to determine reference values for NSE in newborns and young infants and to assess whether NSE levels in early infancy (i.e., preterm infants and term infants) differ from the adult reference range for this enzyme. Methods: We enrolled 140 healthy babies, which included 40 preterm newborns (3-15 days old and born at 28-42 weeks gestation), 40 term newborns (< 1 month old and born at term), and 60 young infants 1-3 months old (n = 20 per subgroup of 1-, 2-, and 3-month-old infants). The determination of NSE levels was performed by the electrochemiluminescence immunoassay (ECLIA) method using the Elecysys 2010 device (Roche Diagnostics, Mannheim, Germany). The mean serum NSE levels for the preterm newborns was 21.83 +/- 15.06 ng/mL [95% confidence interval (95%Cl), 16.95-26.71 ng/mL]; term newborns, 18.06 +/- 12.83 ng/mL (95%Cl, 13.94-22.19 ng/mL); and young infants, 9.09 +/- 4.38 ng/mL (95%Cl, 7.96 -10.23 ng/mL). The mean serum NSE level for infants 1-3 months old was within the ECLIA kit's normal range (4.7-18 ng/mL for adults), whereas the corresponding means for the preterm and term newborns were higher (p < 0.001, for both). Conclusion: Our findings suggest that adult reference values should not be applied to the pre-term and term age groups. Copyright (C) 2014, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy
(2018) Haberal, Mehmet; Haberal, Nihan; Baris, Zeren; Ozcay, Figen; Ozbek, Ozlem Yilmaz; Sarialioglu, Faik; 29755021; AAB-4153-2020
Background/Aims: We evaluated our 16-year single-center experience of pediatric post-transplant lymphoproliferative disorder (PTLD) cases who underwent liver transplantation between 2001 and 2017. Materials and Methods: Of the 236 pediatric patients who underwent liver transplantation between 2001 and 2017, the clinical and laboratory data of eight patients diagnosed with PTLD were reviewed. The pre-transplant Epstein-Barr virus (EBV) status of 172 patients was also recorded. Results: The total incidence of PTLD was 3.4%. The incidence of PTLD was 10% in pre-transplant EBV immunoglobulin G (IgG)-seronegative patients and 0.8% in pre-transplant EBV IgG-seropositive patients. The mean age of the patients at liver transplantation was 2.71 +/- 3.21 years, and four patients were aged below 1 year at the time of transplantation. PTLD was diagnosed at 21.81 +/- 18.1 months after transplantation. The primary site of involvement was variable among patients: peripheral and mediastinal lymph nodes, stomach and intestine, transplanted graft, bone marrow, and nasopharynx. The eosinophil count varied greatly among patients, with a mean value of 524.62 +/- 679/mm3. Three patients had a food allergy and were administered an elimination diet at the time of PTLD diagnosis. Six patients had PTLD of B-cell origin. One patient died due to neutropenic sepsis during chemotherapy, whereas seven patients were followed up in full remission for 7.75 +/- 4 years. Conclusion: PTLD is a life-threatening complication of solid-organ transplantation with a heterogeneous clinical spectrum. Food allergy had a close association with PTLD. A close follow-up of patients with risk factors and an early diagnosis with appropriate treatment may lead to a better outcome.
An Unusual Site, Breast Involvement in An Adolescent Girl with Burkitt's Lymphoma
(2015) Yazici, Nalan; Sarialioglu, Faik; Nursal, Gul Nihal; Pourbagher, Aysin; Demir, Senay; Kocer, Nazim Emrah; 0000-0002-8257-810X; 0000-0002-5302-4386; 0000-0002-4209-9075; 0000-0002-5943-9283; AAL-7766-2021; R-3735-2016; AAM-5138-2021; AAK-9310-2021; AAM-5436-2021
Use of Proporanolol Compounding from Tablet in Infantile Hemangiomas
(2017) Yazici, Nalan; Sarialioglu, Faik; Erbay, Ayse; 0000-0002-8257-810X; 0000-0003-4465-8229; 28612583; AAL-7766-2021; AAM-5138-2021
Variability of Dose and Level of Sirolimus in a Patient With Tuberous Sclerosis Complex and Subependymal Giant Cell Astrocytoma
(2016) Yazici, Nalan; Sarialioglu, Faik; Alkan, Ozlem; Erol, Ilknur; Erbay, Ayse; 0000-0003-4465-8229; 0000-0002-3530-0463; 0000-0001-7526-3460; 0000-0002-8257-810X; 27082208; AAM-5138-2021; AAK-4825-2021; AAM-4169-2021; AAL-7766-2021